Hepatitis C Patient Management and Family Health Education
Health Education Based on We Media to Promote Patient Adherence to HCV Treatment: A Nationwide Online Randomized Controlled Trial
INTRODUCTION: Hepatitis C virus (HCV) is recognized as the leading cause of chronic liver disease worldwide. However, the screening rate and treatment rate of HCV-infected patients in China is low, which increases the burden of patients and the infection risk of their family members. WeChat, an instant messaging software, is used in a very high proportion in China. Health promotion based on WeChat public platform is a very convenient and effective way of health education. Therefore, this study plans to apply WeChat to conduct health intervention for HCV-infected patients. The objective is to explore the effect of We-media-based health promotion method on the detection rate and treatment rate of HCV-infected and their family members.
METHOD: Recruitment will be conduct in 10 hospitals in Jilin, Beijing, Henan and Anhui provinces. The subjects should be patients new diagnosed with hepatitis C at the hospital and aged 18 to 69. After signing the consent form, eligible participants were selected through the inclusion and exclusion criteria. 1000 participants will be recruited for the trial. After completing an baseline reseach by a online questionnaire, patients will be randomly assigned to receive a targeted short article on HCV weekly or a general health article with no mention of HCV. The intervention will last three months and a follow-up will be conduct at three month after the last intervention.
OUTCOMES: The primary outcome is antiviral therapy. The secondary outcomes are cognition and attitude towards hepatitis C, factors influencing antiviral therapy, time to first treatment and the compliance of treatment.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Permanent residents in the province
- Ages 18-69 (inclusive)
- Both blood anti-HCV test and HCV-RNA test is positive
- Familiar with the use of mobile phones and WeChat
- Informed consent and voluntary participation in the study
Exclusion Criteria:
- Temporary staff who come to the city to work, travel or visit relatives, or those who will be living in other cities for a long time
- Suffering from other serious diseases
- Patients with mental disorder or memory disorder
- Pregnant women or those who have a plan to prepare for pregnancy within one year
- Refuse to participate in the investigation
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: intervenční skupina
|
The intervention group receive a targeted short article on HCV from WeChat weekly.
|
|
Jiný: kontrolní skupina
|
The control group receive a general health article with no mention of HCV from WeChat weekly.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Rate of antiviral therapy
Časové okno: 6 months after the first intervention
|
The rate of antiviral therapy is equal to the number of subjects received antiviral therapy divide by the number of all subjects.
|
6 months after the first intervention
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Time to first treatment
Časové okno: 6 months after the first intervention
|
This is the interval time between the first intervention and first treatment.
We want to know from this outcome how long it takes the subject to receive the health intervention before starting treatment.
Thus, we can analyze the relationship between intervention time and treatment behavior.
|
6 months after the first intervention
|
|
Cognition and attitude towards hepatitis C
Časové okno: 6 months after the first intervention
|
Investigators designed a standardized questionnaire that asked questions about subjects' knowledge and attitudes toward hepatitis C. The scores of the questionnaire were used to evaluate the cognition and attitude of the subjects.
|
6 months after the first intervention
|
|
Factors influencing antiviral therapy
Časové okno: 6 months after the first intervention
|
The investigators designed a ranking question of factors that interfered with the subjects' treatment in the questionnaire.
These factors include: (1) My condition is not serious; (2) I am worried about the side effects of treatment; (3) I am afraid of being discriminated against because someone know I have the disease; (4) I have financial difficulties (or the treatment costs are too high); (5) The process of visiting a doctor is complicated.
Subjects can also fill in their own ideas in the blank if they have other factors not mentioned in this questionnaire.
Investigators will analyze the extent to which each factor affects a patient's treatment.
|
6 months after the first intervention
|
|
The rate of giving up treatment halfway
Časové okno: 6 months after the first intervention
|
This rate is used to assess compliance with treatment.
This rate is equal to the number of subjects who give up treatment halfway divided by the number of subjects who get treatment.
|
6 months after the first intervention
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Fuqiang Cui, PhD, Peking University
- Vrchní vyšetřovatel: Tianshuo Zhao, Study Director
- Vrchní vyšetřovatel: Yingsheng Shen, China Liver Health
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Očekávaný)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- IN-CN-987-5377
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .